Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Share your aches,pains,experiences,joys and cures. -- Ignore unavailable to you. Want to Upgrade?

To: Travis_Bickle who wrote (122)	3/30/2007 3:54:51 PM
From: Patricia Trinchero	Respond to of 1564

That is good news but the safety trials will be a bugger............one molecular slip by those ever so often mutating virus's and they might attack normal brain cells as well as the cells with the amyloid plaques. It's certainly a start but there's a long road to travel between a successful mouse study and a FDA approved drug. That road is full of pot holes !! The good news is that many companies are working on Alzheimers cause the market for it is huge...........a cure will be a multi billion ( maybe trillion ) dollar drug.